Retatrutide in the UK and Europe: Regulatory Pathway and Expected Timeline

Current Global Status: Not Approved Anywhere

Retatrutide (LY3437943) is not approved for any indication in any country as of March 2026. No regulatory authority — including the FDA, MHRA, EMA, or any other national agency — has received a marketing authorization application for the drug. Eli Lilly’s TRIUMPH Phase 3 program is ongoing, with TRIUMPH-4 reporting topline results in December 2025 showing -28.7% mean body weight reduction at the 12 mg dose over 68 weeks.

For patients in the United Kingdom and Europe, understanding when retatrutide might become available requires examining the regulatory pathways specific to these jurisdictions, which operate on different timelines than the FDA process.

The FDA-First Strategy

Eli Lilly, like most large pharmaceutical companies, pursues a sequential regulatory strategy that begins with the United States. This is driven by the size of the US market and the fact that the FDA process is well-established for obesity therapeutics.

The current US timeline:

NDA filing: Expected late 2026, per Eli Lilly’s Q4 2025 earnings guidance
FDA decision: Mid-2027 (optimistic, if Priority Review granted) to early 2028 (standard review)

This matters for UK and European patients because both the MHRA and EMA typically evaluate new molecular entities after the FDA has acted. The FDA decision becomes the anchor point from which UK and EU timelines extend.

UK Regulatory Pathway: The MHRA

Post-Brexit MHRA Independence

Since January 2021, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has operated independently of the European Medicines Agency. The MHRA maintains its own assessment process for new drugs, with several pathway options relevant to retatrutide.

The International Recognition Procedure

The MHRA introduced the International Recognition Procedure (IRP) as a reliance pathway that allows it to reference regulatory decisions made by trusted partner agencies, including the FDA, EMA, Health Canada, and others. Under this procedure, the MHRA can leverage the FDA’s review rather than conducting a fully independent assessment from scratch.

This significantly shortens the UK approval timeline for drugs that have already been assessed by the FDA. The MHRA’s target timeline under IRP is 67 working days (approximately 3 months) from submission acceptance to decision, though real-world timelines vary.

Tirzepatide Precedent in the UK

The best predictor of retatrutide’s UK pathway is the trajectory of tirzepatide (Mounjaro/Zepbound), Eli Lilly’s other incretin-based therapy:

FDA approval (Zepbound, obesity): November 2023
MHRA approval (Mounjaro, type 2 diabetes): March 2024 — approximately 22 months after the FDA approved Mounjaro for type 2 diabetes in May 2022

This compressed timeline reflects the MHRA’s use of reliance pathways and the agency’s stated goal of ensuring UK patients have timely access to innovative medicines. However, retatrutide’s novel triple-receptor mechanism and the dysesthesia safety signal (20.9% at 12 mg in TRIUMPH-4) may require more extensive MHRA review than a familiar dual-agonist mechanism.

Estimated UK MHRA Timeline

Based on the FDA timeline and MHRA patterns: earliest late 2027, more likely mid-2028 for MHRA marketing authorization. This assumes Eli Lilly files with the MHRA shortly after or concurrently with the FDA decision, using the International Recognition Procedure.

EU Regulatory Pathway: The EMA

Centralized Marketing Authorization

The European Medicines Agency uses a centralized procedure that grants a single marketing authorization valid across all EU/EEA member states. This is the mandatory pathway for new active substances indicated for obesity and diabetes. The process involves assessment by the Committee for Medicinal Products for Human Use (CHMP), which issues a scientific opinion, followed by a European Commission decision.

Typical EMA Timeline

The standard EMA assessment timeline is 210 active days (approximately 12-15 calendar months including clock stops for the applicant to respond to questions). In practice, the total elapsed time from application to CHMP opinion is typically 12-18 months.

Tirzepatide Precedent in the EU

Tirzepatide’s EU trajectory illustrates the typical lag:

FDA approval (Mounjaro, diabetes): May 2022
EMA approval (Mounjaro, diabetes): October 2022 — approximately 5 months later
FDA approval (Zepbound, obesity): November 2023
EMA approval (Zepbound, obesity): December 2024 — approximately 13 months later

The obesity indication took substantially longer than the diabetes indication at the EMA level, reflecting the more cautious European regulatory posture toward weight management drugs and the need for independent EMA assessment of the full obesity dataset.

Estimated EU EMA Timeline

Based on these precedents: earliest early 2029, more likely late 2029 for EMA marketing authorization. The triple-agonist mechanism is novel, and the EMA may require additional time to evaluate the glucagon receptor component and the dysesthesia signal.

NICE Assessment: The UK Access Bottleneck

What NICE Does

In England and Wales, MHRA approval alone does not guarantee NHS availability. The National Institute for Health and Care Excellence (NICE) must conduct a health technology assessment (HTA) to determine whether a drug represents acceptable value for money for the NHS. This cost-effectiveness evaluation compares the clinical benefit against the price, using quality-adjusted life years (QALYs) as the primary metric.

GLP-1 Drugs and NICE: A Mixed Record

NICE assessments of GLP-1 receptor agonists for obesity have produced varied outcomes:

Semaglutide (Wegovy): NICE recommended with restrictions, limiting use to specialist weight management services and imposing stopping rules if weight loss targets are not met at defined intervals
Tirzepatide (Mounjaro, diabetes): NICE approved for type 2 diabetes
Tirzepatide (Zepbound, obesity): NICE assessment was still ongoing as of March 2026

The cost-effectiveness threshold for obesity drugs is particularly challenging because NICE must model the long-term health benefits of sustained weight loss against the ongoing cost of treatment. Drugs that require indefinite use face higher bars than one-time interventions.

Timeline Impact

NICE assessments typically add 6-12 months to the availability timeline after MHRA approval. In some cases, NICE begins its assessment in parallel with the MHRA review, which can compress the gap. However, for a novel mechanism like retatrutide, NICE may wait for the MHRA decision before initiating its own process.

Estimated NICE timeline: 6-12 months after MHRA approval, putting NHS availability at earliest late 2028, more likely mid-2029.

Private Prescription Access

Patients in the UK may be able to access MHRA-approved drugs through private prescriptions before NICE completes its assessment. This occurred with tirzepatide — private clinics began prescribing Mounjaro before NICE had finalized its guidance. However, private access means full out-of-pocket cost without NHS subsidy.

Phase 3 Trial Sites in Europe

Eli Lilly’s TRIUMPH program is a global development program with clinical trial sites across multiple continents, including sites in the United Kingdom and EU member states. Active participation in Phase 3 trials in these regions can facilitate regulatory submissions because the MHRA and EMA prefer to see data that includes their own patient populations.

European trial sites also mean that some UK and EU patients may have early access to retatrutide through clinical trial enrollment. Sites can be identified on ClinicalTrials.gov by searching for “retatrutide” or “LY3437943” and filtering by location.

Realistic Timeline Summary

United Kingdom (MHRA + NICE)

Milestone	Estimated Timeline
FDA decision (anchor point)	Mid-2027 to early 2028
MHRA marketing authorization	Late 2027 to mid-2028
NICE cost-effectiveness decision	Late 2028 to mid-2029
NHS availability	Earliest late 2028, more likely mid-2029
Private prescription availability	After MHRA approval, potentially late 2027 to mid-2028

European Union (EMA)

Milestone	Estimated Timeline
FDA decision (anchor point)	Mid-2027 to early 2028
EMA submission	Mid-2027 to late 2027
CHMP opinion	Late 2028 to mid-2029
EC marketing authorization	Earliest early 2029, more likely late 2029
Individual country reimbursement	Varies by member state, additional 6-18 months

These estimates assume no major regulatory setbacks, a clean FDA review, and a straightforward safety profile assessment for the dysesthesia signal. Actual timelines may shift in either direction.

Frequently Asked Questions

Can I get retatrutide in the UK right now?

No. Retatrutide is not approved anywhere in the world as of March 2026. It cannot be legally prescribed in the UK. Any website claiming to sell retatrutide for human use is operating outside regulatory oversight, and the product has no quality or safety assurance. The only legitimate access route is through clinical trial enrollment.

Will the UK approve retatrutide before the EU?

Based on current regulatory patterns, yes. The MHRA’s International Recognition Procedure allows it to leverage the FDA’s review and act more quickly than the EMA’s centralized procedure. The tirzepatide precedent supports this — the MHRA approved Mounjaro several months before the EMA completed its own process.

Will retatrutide be available on the NHS?

NHS availability depends on a positive NICE assessment, which evaluates whether the drug represents acceptable value for money. Given the mixed track record of obesity drugs at NICE, this is not guaranteed. If NICE declines to recommend retatrutide, it could still be available via private prescription at full cost.

How long does NICE assessment typically take?

NICE health technology assessments for new drugs typically take 6-12 months from initiation to final guidance. In some cases, NICE begins its assessment before MHRA approval is granted, running the processes in parallel. For complex submissions involving novel mechanisms, the process can take longer.

Should I consider traveling abroad for retatrutide?

As of March 2026, retatrutide is not approved in any country. Even after potential FDA approval in 2027-2028, accessing a prescription drug from another jurisdiction involves legal, logistical, and safety complexities. Patients should discuss currently approved alternatives (such as semaglutide and tirzepatide) with their healthcare providers rather than pursuing unauthorized access.

Key Takeaways

Not approved anywhere: Retatrutide has no marketing authorization in any country as of March 2026
FDA first: Eli Lilly’s US NDA filing is expected in late 2026, with FDA decision in mid-2027 to early 2028
UK (MHRA): Earliest late 2027 for MHRA approval, using the International Recognition Procedure
UK (NHS): NICE assessment adds 6-12 months — NHS availability earliest late 2028, likely mid-2029
UK (private): Private prescriptions may be available after MHRA approval, before NICE completes its review
EU (EMA): Centralized authorization earliest early 2029, more likely late 2029
EU (reimbursement): Individual member states set their own reimbursement timelines after EMA approval
Clinical trials: The only legitimate way to access retatrutide today, including at European sites